PEG-intron [peginterferon alfa-2b] plus Rebetol [ribavirin] for the treatment of subjects with chronic hepatitis C who failed to respond to previous combination therapy (any alpha interferon treatment in combination with ribavirin)
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 28 Mar 2011 Actual initiation date for the extension trial [NCT00049842] is October 2002 actual patient number is 540.
- 28 Mar 2011 Tial status for the extension trial [NCT00049842] is completed.
- 28 Mar 2011 Actual end date for the extension trial [NCT00049842] is October 2009